Akroswiss, a Zug, Switzerland-based developer of an innovative and patented Midazolam-based nasal spray to treat patients suffering from claustrophobia and epileptic seizures, raised several million Swiss Franc in a strategic seed funding round.
Backers included the family investment group Linsi, radiologist and primary user Prof. Dr. med. Bernhard Schuknecht as well as existing investor Walter P. Hölzle.
The company intends to use the funds to further product development, conduct clinical studies, and initiate the medical device regulatory process to complement EMA’s requirements for data package submission.
Led by Marc Froehlich, CEO, Akroswiss has developed and tested a Bi-dose nasal drug delivery device for Midazolam with a first-class 360° functionality. The development of these Midazolam medicines comes in two independent indications: (1)Product for premedication ahead of diagnostic and therapeutic interventions against claustrophobia and restlessness, (2) product for the rescue treatment in epileptic seizure patients.